Loading…
← CockpitCompetitor Analysis › KYMR Kymera Therapeutics, Inc.Open in the cockpit ↗

Kymera Therapeutics, Inc.KYMRCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Biotech pioneering 'targeted protein degrader' drugs that eliminate disease-causing proteins, focused on immunology and inflammation.

Momentum leader 88
Mkt cap
$10.3B
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$126M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-59.6 pp
WACC 15.2%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$121.13
1D-0.3%
1W-10.2%
1M+6.8%
3M-0.3%
6M+50.2%
YTD+55.7%
1Y+89.0%
ATR %5.5%
Beta0.83
52w lowhigh15.2% off high

What Kymera Therapeutics does

Biotech pioneering 'targeted protein degrader' drugs that eliminate disease-causing proteins, focused on immunology and inflammation.

Has no approved medicine, so income comes from partners: upfront and milestone payments from Sanofi and Gilead under research collaborations and licences. Spending goes on clinical trials of its own oral drugs, led by KT-621 for immune diseases. The business is funded by partner payments and cash raised from investors.

Products and services

  • KT-621 (STAT6 degrader, atopic disease pipeline)
  • Partnered pipeline (Sanofi IRAK4, Gilead deals)

Customers

  • Immunologists/dermatologists treating inflammatory
  • Pharma partners licensing the degrader platform

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • Targeted protein degradation drug…

What could go right

  • KT-621 clinical data readouts (oral biologic-like efficacy)
  • Additional pharma partnership deals

What could go wrong

  • Binary clinical trial risk on a pre-revenue pipeline
  • Competitive degrader-technology landscape

Moat: narrow (IP / patents, process know-how). Early leadership in oral targeted-protein-degrader chemistry, patent-protected, with validated pharma partnerships.

Headquarters: Watertown, Massachusetts, US · Founded: 2016 · Employees: 238

Named competitors

Kymera Therapeutics at a glance

Size Kymera Therapeutics (KYMR) is a United States Health Care company (Biotechnology) with a market value of $10.3B, the 749th largest of 3,085 United States companies the cockpit tracks. Shares closed at $121.13 on 18 Nov 2026.

Performance Over six months the shares gained 50.2%, against +23.0% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 133.8% over the last twelve months (peer median +25.6%); the operating margin is -396.0% (peer median 10.9%).

Valuation It trades at 92.4× enterprise value to sales against a peer median of 9.5× (2nd most expensive of 17).

Capital Return on invested capital runs 59.6 points below its cost of capital (15.2% WACC).

Backlog Backlog (remaining performance obligations) was $51.4M at 31 Dec 2024 — 1.1 years of trailing revenue. Backlog detail →

Short interest Short interest is 9.8% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515017521 May 202621 Aug 202618 Nov 2026KYMR 150Peer median 119
Six months, rebased to 100: Kymera Therapeutics against the median of its 20 peers (local-currency closes).

Kymera Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$102M$39.2M$47.1M$78.6M$46.8M
Revenue growth—-17%-40%+68%—
Gross profit$94.1M$30.9M$39.7M$75.0M$43.8M
EBITDA-$397M-$337M-$249M-$162M-$158M
Net income-$349M-$311M-$224M-$147M-$155M
Free cash flow-$289M-$234M-$207M-$137M-$156M
Capital expenditure$1.33M$1.45M$12.8M$34.5M$2.84M
Total debt$76.6M$82.3M$87.8M$84.7M$17.3M

Quarterly statements and history in the cockpit →

Kymera Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%002422HALOTECHKRYSPCVXBMRN10931961701548SMMTELANTWSTTXGCGONAXSMBBIOIMVTNBIXKODKYMR6-month return →1-month return →
Up and to the right = strong over both horizons. Kymera Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×500×1,000×002422HALOTECHKRYS196170CGONBBIOARWRKYMRRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Kymera Therapeutics is the large dot.

Kymera Therapeutics competitors and peer comparison

Head to head with its named competitors (KYMR vs ARVN vs CCCC vs NRIX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Kymera Therapeutics KYMR$10.3B+50%+134%-396%92.4×n/a
Arvinas ARVN$443M-26%-12%-10%n/an/a
C4 Therapeutics CCCC$325M-25%+7%-316%5.4×n/a
Nurix Therapeutics NRIX$1.54B-14%+739%41%0.8×n/a

How Kymera Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kymera Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureKYMRPeer medianRank in peer set
1-month return+6.8%-5.4%7th highest of 21
6-month return+50.2%+23.0%6th highest of 21
Distance from 52-week high-15.2%-26.2%7th highest of 21
Revenue growth (TTM)+133.8%+25.6%3rd highest of 17
Operating margin-396.0%10.9%2nd lowest of 17
EV / Sales92.4×9.5×2nd most expensive of 17
ROIC minus cost of capital-59.6 pp-1.0 pp2nd lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Kymera Therapeutics KYMRUnited States$10.3B+50%+134%-396%92.4×n/an/a
Sichuan Kelun Pharmaceutical 002422.SZChina$10.1B+35%0%9%3.7×6.2%+2.3%
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%7.3×-0.3%+39.2%
Bio-Techne TECHUnited States$11.4B+56%+1%21%9.2×31.6%+5.5%
Krystal Biotech KRYSUnited States$9.34B+4%+26%48%18.0×13.1%+26.0%
Vaxcyte PCVXUnited States$9.26B+24%n/an/an/an/an/a
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%4.2×8.2%+12.0%
Cspc Pharma 1093.HKHong Kong$12.0B+10%+25%28%2.1×-10.7%+0.1%
ALTEOGEN 196170.KSSouth Korea$8.80B-56%+61%53%35.1×24.6%+38.5%
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%9.8×36.9%+19.8%
Summit Therapeutics SMMTUnited States$8.40B-41%n/an/an/an/an/a
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%3.2×32.9%+7.6%
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%16.2×n/an/a
10x Genomics TXGUnited States$7.51B+138%-4%-11%11.3×47.2%+16.6%
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%1,000.7×n/an/a
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%8.0×n/an/a
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%19.1×n/an/a
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%4.4×-1.5%+22.3%
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%14.0×n/an/a

Kymera Therapeutics backlog

Kymera Therapeutics reported $51.4M of remaining performance obligations at 31 Dec 2024 and up 3% from the previous quarter. That is 1.1 years of trailing revenue already under contract. Book-to-bill last quarter: 1.23.

Questions

Who are Kymera Therapeutics's main competitors?
Named competitors: Arvinas (ARVN), C4 Therapeutics (CCCC), Nurix Therapeutics (NRIX). The cockpit's measured peer set (industry) also includes Sichuan Kelun Pharmaceutical (002422.SZ), Halozyme Therapeutics (HALO), Bio-Techne (TECH), Krystal Biotech (KRYS), Vaxcyte (PCVX), BioMarin Pharmaceutical (BMRN).
Is Kymera Therapeutics expensive compared with its peers?
On ev / sales it trades at 92.4× against a peer median of 9.5×, 2nd most expensive of 17 in its peer set.
How has Kymera Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +50.2% against +23.0% for the median peer; over one year +89.0%.
What is Kymera Therapeutics's backlog?
Kymera Therapeutics's remaining performance obligations (contracted revenue not yet recognised) were $51.4M at 31 Dec 2024.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.